Abstract: Kirsten Rat Sarcoma （KRAS） gene is the first proto-oncogene identified in human tumors. With the advancement of genome sequencing technology and accumulation of database, the genomic alteration profile, molecular and cellular biological characteristics of KRAS mutant tumors have been extensively and thoroughly studied. Deeply exploring the vulnerabilities in KRAS signaling pathway is helpful for drug development. In recent years, breakthrough has been made that small molecule KRAS G12C inhibitors demonstrated effective anti-tumor activity. In this review, we summarize the gene mutation profile, potential weaknesses of KRAS signaling pathway and the development of novel clinical treatment schemes in KRAS mutant lung cancer.